Signos Co-Founder and CEO Sharam Fouladgar-Mercer was featured in a profile exploring how continuous glucose monitoring is reshaping weight management. The article highlights Signos as the first FDA-cleared glucose monitoring platform for weight management, pairing real-time CGM data with AI-driven insights to help individuals better understand and respond to their metabolic patterns.
The feature outlines Signos’ clinical study involving 35,000 participants and its rapid growth as interest in personalized metabolic health increases. By focusing on real-time feedback and sustainable behavior change rather than pharmaceutical intervention, Signos is positioning itself at the intersection of health technology, data-driven wellness, and long-term lifestyle optimization.